These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 31399960)
1. Current Opinion for Hypertension in Renal Fibrosis. Sun HJ Adv Exp Med Biol; 2019; 1165():37-47. PubMed ID: 31399960 [TBL] [Abstract][Full Text] [Related]
3. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
4. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases]. Horký K Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582 [TBL] [Abstract][Full Text] [Related]
5. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients. Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428 [TBL] [Abstract][Full Text] [Related]
6. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Kavvadas P; Weis L; Abed AB; Feldman DL; Dussaule JC; Chatziantoniou C Hypertension; 2013 Apr; 61(4):901-7. PubMed ID: 23438929 [TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Ruilope LM Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118 [TBL] [Abstract][Full Text] [Related]
8. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373 [TBL] [Abstract][Full Text] [Related]
9. Contribution of genetics and epigenetics to progression of kidney fibrosis. Tampe B; Zeisberg M Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv72-9. PubMed ID: 23975750 [TBL] [Abstract][Full Text] [Related]
12. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Nadar SK; Tayebjee MH; Messerli F; Lip GY Curr Pharm Des; 2006; 12(13):1581-92. PubMed ID: 16729871 [TBL] [Abstract][Full Text] [Related]
13. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. Flack JM; Peters R; Shafi T; Alrefai H; Nasser SA; Crook E J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S92-8. PubMed ID: 12819310 [TBL] [Abstract][Full Text] [Related]
14. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. Mulè G; Castiglia A; Cusumano C; Scaduto E; Geraci G; Altieri D; Di Natale E; Cacciatore O; Cerasola G; Cottone S Adv Exp Med Biol; 2017; 956():279-306. PubMed ID: 27873229 [TBL] [Abstract][Full Text] [Related]
15. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Cooper ME Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106 [TBL] [Abstract][Full Text] [Related]
16. N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. Mattace Raso G; Simeoli R; Russo R; Santoro A; Pirozzi C; d'Emmanuele di Villa Bianca R; Mitidieri E; Paciello O; Pagano TB; Orefice NS; Meli R; Calignano A Pharmacol Res; 2013 Oct; 76():67-76. PubMed ID: 23917217 [TBL] [Abstract][Full Text] [Related]
17. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Remuzzi G; Perico N; Macia M; Ruggenenti P Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Hollenberg NK; Raij L Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Frenay AR; Yu L; van der Velde AR; Vreeswijk-Baudoin I; López-Andrés N; van Goor H; Silljé HH; Ruifrok WP; de Boer RA Am J Physiol Renal Physiol; 2015 Mar; 308(5):F500-9. PubMed ID: 25503732 [TBL] [Abstract][Full Text] [Related]
20. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Burrell LM; Burchill L; Dean RG; Griggs K; Patel SK; Velkoska E Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]